{"nctId":"NCT01642901","briefTitle":"Zoledronic Acid in Acute Spinal Cord Injury","startDateStruct":{"date":"2012-09","type":"ACTUAL"},"conditions":["Spinal Cord Injury"],"count":16,"armGroups":[{"label":"Zoledronic Acid 5 mg IV infusion","type":"EXPERIMENTAL","interventionNames":["Drug: Zoledronic acid"]},{"label":"normal saline 0.9%","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: normal saline 0.9%"]}],"interventions":[{"name":"Zoledronic acid","otherNames":["Reclast"]},{"name":"normal saline 0.9%","otherNames":["normal saline","0.9% saline"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ages 18-65, male or female\n* Traumatic SCI with Neurological level C4-T10, American Spinal Injury Association (ASIA) Impairment Scale (AIS) A,\n* Serum calcium level \\>7.0 mg/dL) at time of study drug administration\n* Screening baseline serum 25-hydroxy (25-OH) vitamin D of at least 13 ng/ml\n* No medical contraindication to supplemental vitamin D for participants whose levels are \\>13 ng/ml but sub-therapeutic (\\<32ng/ml)\n* No medical contraindication to supplemental calcium\n* Weight under 300 pounds, which is the maximum permitted on the dual-energy X-ray absorptiometry (DXA) scanner\n\nExclusion Criteria:\n\n* Ventilator-dependent individuals\n* Chronic steroid use (defined as \\>6 months)\n* Rheumatoid disease with use of prior disease modifying anti-rheumatic drugs (DMARDs) affecting bone density\n* History of osteoporosis or of treatment for osteopenia or osteoporosis with bisphosphonates, or selective reuptake estrogen modifying agents\n* Current use of medications\\* including bisphosphonates to treat osteoporosis (\\*note that prior calcium or vitamin D use is not an exclusion criteria)\n* History of more than one lower extremity osteoporosis-related fracture\n* Chronic renal insufficiency, creatinine clearance \\< 35 ml/min, during screening\n* End stage liver or kidney disease\n* Medical conditions resulting in hypogonadal states that affect bone density\n* Uncontrolled thyroid disease/thyrotoxicosis\n* Hereditary or acquired metabolic bone disorder\n* History of use of unfractionated heparin for \\>1 year\n* History of selected antiseizure medications, specifically phenobarbital, phenytoin, carbamazepine, sodium valproate \\>1 year\n* Acute or chronic bilateral lower extremity fractures involving tibia or femur, with placement of surgical hardware in any areas of above locations\n* Severe hypotension requiring use of intravenous blood pressure agents such as dopamine, norepinephrine or phenylephrine. Exception may allow for patients on pressors who arm experiencing hypotension as they acclimate to upright posture.\n* Inability to provide informed consent and understand the consent process\n* Facial fractures requiring oral surgery\n* Dental surgery or oral maxillofacial surgery within 2 weeks of anticipated study drug administration\n* Pregnancy present on admission\n* Vitamin D deficiency on admission testing (serum 25-OH D reported as \\< 13 ng/mL)\n* Patients with an established reaction to, or history of, anaphylactic shock to aspirin","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Areal Bone Mineral Density at Hip","description":"Percent change in areal bone mineral density (aBMD) assessed by dual energy X-ray absorptiometry (DXA) at 4 months compared to baseline.\n\nThis will compare aBMD at the hip.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":"7.14"},{"groupId":"OG001","value":"-12.0","spread":"7.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":"7.77"},{"groupId":"OG001","value":"-12.9","spread":"7.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"6.12"},{"groupId":"OG001","value":"-9.37","spread":"6.39"}]}]}]},{"type":"PRIMARY","title":"Change in Areal Bone Mineral Density at Knee","description":"Percent change in areal bone mineral density (aBMD) assessed by dual energy X-ray absorptiometry (DXA) at 4 months compared to baseline.\n\nThis will compare aBMD at the distal femur and proximal tibia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"4.46"},{"groupId":"OG001","value":"-6.75","spread":"4.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"11.7"},{"groupId":"OG001","value":"-8.56","spread":"14.1"}]}]}]},{"type":"PRIMARY","title":"Change in Areal Bone Mineral Density at Hip","description":"Percent change in areal bone mineral density (aBMD) assessed by dual energy X-ray absorptiometry (DXA) at 12 months post-injury compared to baseline.\n\nThis will compare aBMD at the hip.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.2","spread":"3.64"},{"groupId":"OG001","value":"-21.3","spread":"8.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.62","spread":"4.70"},{"groupId":"OG001","value":"-19.4","spread":"7.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.93","spread":"5.60"},{"groupId":"OG001","value":"-17.0","spread":"11.8"}]}]}]},{"type":"PRIMARY","title":"Change in Areal Bone Mineral Density at Knee","description":"Percent change in areal bone mineral density (aBMD) assessed by dual energy X-ray absorptiometry (DXA) at 12 months post-injury compared to baseline.\n\nThis will compare aBMD at the distal femur and proximal tibia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.07","spread":"5.2"},{"groupId":"OG001","value":"-10.0","spread":"8.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.54","spread":"9.89"},{"groupId":"OG001","value":"-10.0","spread":"18.3"}]}]}]},{"type":"SECONDARY","title":"Change in Biomarkers of Bone Resorption (sCTX)","description":"Change in sCTX from baseline to 1- and 4-months post intervention and 12-months post-injury.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-64.1","spread":null},{"groupId":"OG001","value":"14.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.9","spread":null},{"groupId":"OG001","value":"23.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.6","spread":null},{"groupId":"OG001","value":"-5.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Biomarkers of Bone Formation (P1NP)","description":"Change in serum P1NP from baseline to 1- and 4-months post intervention.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.66","spread":null},{"groupId":"OG001","value":"65.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.43","spread":null},{"groupId":"OG001","value":"27.45","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability of Zoledronic Acid","description":"Assessment of the safety and tolerability of zoledronic acid in the acute spinal cord injury population. This will be done by examination reportable adverse events including fevers, flu-like symptoms, GI upset as measures of safety and report of patient's willingness to have participate in physical therapy in the first week after receiving medication as a measure of tolerability","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":10},"commonTop":["Fever","Flu-like symptoms","elevated creatine phosphokinase (CPK)"]}}}